Warfarin and phenprocoumon: Experience of an Outpatient Anticoagulation Clinic;Warfarina y femprocumona: Experiencia de una Unidad de Anticoagulación

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 1, 2010, Pages 40-43

  Leiria, Tiago Luiz Luz ^a   Pellanda, Lucia ^a   Miglioranza, Marcelo Haertel ^a   Sant'Anna, Roberto Tofani ^a   Becker, Lucas S ^a   Magalhães, Eros ^a   De Lima, Gustavo Glotz ^a  

^a INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

Author keywords

Anticoagulants; Anticoagulants administration dosage; Hemorrhage; Phenprocumon; Warfarin

Indexed keywords

PHENPROCOUMON; PROTHROMBIN; WARFARIN;

ADULT; ADVERSE OUTCOME; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

EID: 77951615045     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991; 84: 527-539
2. Gohlke-Barwolf C, Acar J, Oakley C, Butcgart E, Burckhart D, Bodnar E, et al. Guidelines for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 1995; 16: 1320-1330
3. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347: 969-974
4. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists -the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 204S-233S.
5. Prandoni A, Wright I. The anticoagulants: heparin and the Dicoumarin 3,3′-Methylene-Bis-(4-Hydroxycoumarin). Bull NY Acad Med. 1942; 18: 433-458
6. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005; 44 (12): 1227-1246 (Pubitemid 41832565)
7. Fairweather RB, Ansell J, van den Besselaar AM, Brandt JT, Bussey HI, Poller L, et al. Laboratory monitoring of oral anticoagulant therapy: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med. 1998; 122: 768-781 (Pubitemid 28411235)
8. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001; 40: 587-603. (Pubitemid 32758581)
9. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005; 44 (12): 1227-1246 (Pubitemid 41832565)
10. Gadisseur PA, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol. 2002; 117: 940-946
11. Breed WP, Hooff JP, Haanen C. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. Acta Med Scand. 1969; 186: 283-288
12. Fekkes N, Jonge HD, Veltkamp JJ, Biege R, Loeliger EA. Comparative study of the clinical effect of acenocoumarol (Sintrom) and phenprocoumon (Marcoumar) in myocardial infarction and angina pectoris. Acta Med Scand. 1971; 190: 535-540
13. Fihn SD, Gadisseur AA, Pasterkamp E, Van Der Meer FJM, Breukink-Engbers WG, Geven-Boere LM, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003; 90 (2): 260-266
14. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke. 1997; 28 (1): 72-76
15. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: (3 Suppl.): 457S-482S.
16. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP. National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the atrial fibrillation follow-up investigation of sinus rhythm management (AFFIRM) Study. Arch Intern Med. 2005; 165: 1185-1191
17. Evans A, Kalra L. Are results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable in clinical practice? Arch Intern Med. 2001; 161 (11): 1443-1447
18. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991; 18: 349-355
19. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323: 1505-1511